AP747A - Pharmaceutical compositions in the form of a tablet containing famciclovir. - Google Patents
Pharmaceutical compositions in the form of a tablet containing famciclovir. Download PDFInfo
- Publication number
- AP747A AP747A APAP/P/1997/000911A AP9700911A AP747A AP 747 A AP747 A AP 747A AP 9700911 A AP9700911 A AP 9700911A AP 747 A AP747 A AP 747A
- Authority
- AP
- ARIPO
- Prior art keywords
- famciclovir
- tablet
- percentage
- lactose
- pharmaceutical
- Prior art date
Links
- 229960004396 famciclovir Drugs 0.000 title claims abstract description 24
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 229940080313 sodium starch Drugs 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229960004977 anhydrous lactose Drugs 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 229960001375 lactose Drugs 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960001179 penciclovir Drugs 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012453 solvate Chemical class 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A pharmaceutical tablet wherein famciclovir is the active ingredient and wherein the percentage of famciclovir by weight in the tablet is 85% or greater.
Description
PHARMACEUTICAL COMPOSITIONS IN THE FORM OF A
TABLET CONTAINING FAMCICLOVIR
This invention relates to a novel formulation of a pharmaceutical 5 product.
EP-A-182024 (Beecham Group p.I.c.), Example 2 describes a method of the preparation of famciclovir, a compound which is useful as the oral form of the . compound, penciclovir which has antiviral activity against infections caused by herpesviruses, such as herpes simplex type 1, herpes simplex type 2 and varicella zoster virus, and also against Hepatitis B virus. Penciclovir and its antiviral activity is disclosed in Abstract Ρ.VI1-5 ρ. 193 of ’Abstracts of 14th Int. Congress of Microbiology’, Manchester, England 7-13 September 1986 (Boyd et. al.).
Famciclovir is preferably administered in the form of tablets containing 125 mg, 250 mg, 500 mg or 750 mg of active ingredient. As is conventional in tablet compositions, the tablets contain excipients such as lactose, sodium starch glycollate and magnesium stearate such that the total excipient content is at least 15%. Anhydrous lactose is conventionally included as a major excipient to compensate for any potential inconsistencies in the compression properties of the active ingredient.
The higher the percentage excipient content, the greater the tablet size for a tablet of any given dosage. Particularly in the case of tablets containing 500 mg and 750 mg of active ingredient, the large tablet size can affect patient compliance as the oval face of the tablet would measure 18mm x 8.5mm and 21mm x 10mm respectively when the tablet contains about 76% famciclovir.
It has been discovered that it is possible to formulate famciclovir into a tablet containing less than 15% excipients as the compression properties of famciclovir have proved to be sufficiently consistent to permit this.
Accordingly, the present invention provides a pharmaceutical tablet wherein famciclovir is the active ingredient and wherein the percentage of famciclovir by weight in the tablet is 85% or greater.
All values for percentage weight given herein unless otherwise stated are defined in terms of the core of any tablet which may be coated, for example, film coated.
AP/P/ 9 7 / 0 0 9 1 1
AP.00747
-2A suitable tablet contains less than 15%, less than 10%, less than 5% and preferably 0% of anhydrous lactose or other similar excipient such as microcrystalline cellulose.
A suitable tablet contains famciclovir at a percentage weight of greater than 5 85%, 86%, 87%, 88%, 89%, 90% or 91%. The highest possible percentage of famciclovir is preferred. Famciclovir may be in any suitable pharmaceutically acceptable form, such as in the form of a salt, solvate or polymorph. Famciclovir is preferably in an anhydrous, free base form.
Conventional excipients included in the composition of the tablet include 10 hydroxypropyl cellulose, for example up to 5% or up to 3%, sodium starch glycollate, for example up to 15%, 10%, 7% or 5% and magnesium stearate, for example up to 2% or 1%.
The tablets may be coated with any suitable coating used for pharmaceutical tablets.
The tablets may be prepared by conventional compression methods known in the art. In a preferred method, famciclovir is granulated with an excipient such as hydroxypropyl cellulose, in order to minimise the effect of any variations in physical form of the active ingredient. The granules are screened and dried and then blended with any further excipients to form a compression mix. Tablets are compressed to the size and weight appropriate to the required dosage and then optionally coated as desired.
The following Example illustrates the invention.
AP/P/ 9 7 / 0 0 9 1 1
AP . Ο Ο 7 4 7
- 3 EXAMPLE
The percentage values in brackets indicate the percentage values in the famciclovir tablets currently registered by the regulatory authorities for pharmaceuticals, in the
United Kingdom of Great Britain and Northern Ireland, the U.S.A and other countries of the world.
| Constituent | %w/w | %w/w |
| Famciclovir | 91.42 | (75.66) |
| Hydroxypropyl cellulose | 2.83 | (2.34) |
| sodium starch glycollate | 5.00 | (5.00) |
| magnesium stearate | 0.75 | (0.75) |
| anhydrous lactose | 0 | (16.25) |
Approximate Core Weight is 547mg for 500mg dosage and 820mg for 750mg dosage.
For coated tablets, 2.5% of core weight is added by the coating and the coated tablet weighs 560mg for the 500mg dosage and 840mg for the 750mg dosage,.
The tablets are prepared by dry mixing famciclovir with hydroxypropyl 20 cellulose and then granulating the mixture with water in a high shear granulator. The wet mass is screened, dried and milled. The milled granules are blended with sodium starch glycollate and magnesium stearate to produce the compression mix. Tablets are compressed at the size and weight appropriate to the required strength of tablet and then aqueous film coated.
The resulting size of an oval face of a 750mg tablet is 19mm x 9mm and of a 500mg tablet is 17mm x 8mm.
Claims (7)
1. A pharmaceutical tablet wherein famciclovir is the active ingredient and wherein the percentage of famciclovir by weight in the tablet is 85% or greater.
2. A pharmaceutical tablet according to claim 1, containing less than 15% lactose.
3. A pharmaceutical tablet according to claim 1 or 2, containing less than 5% 10 lactose.
4. A pharmaceutical tablet according to claim 1, 2, or 3, containing 0% lactose.
5. A pharmaceutical tablet according to claim 1, 2, 3, or 4, wherein the 15 percentage of famciclovir by weight in the tablet is 90% or greater.
6. A pharmaceutical tablet according to any one of claims 1 to 5, having the
V V 6 0 0 / Z 6 /d/dV
7. A process for the preparation of a tablet according to any one of claims 1 to 6, wherein the famciclovir and excipients are granulated and then compressed to form a tablet.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9600847.9A GB9600847D0 (en) | 1996-01-16 | 1996-01-16 | Pharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9700911A0 AP9700911A0 (en) | 1997-01-31 |
| AP747A true AP747A (en) | 1999-05-03 |
Family
ID=10787105
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1997/000911A AP747A (en) | 1996-01-16 | 1997-01-02 | Pharmaceutical compositions in the form of a tablet containing famciclovir. |
| APAP/P/1998/001298A AP1114A (en) | 1996-01-16 | 1997-01-13 | Indole compounda as anti-inflammatory/analgesic agents. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1998/001298A AP1114A (en) | 1996-01-16 | 1997-01-13 | Indole compounda as anti-inflammatory/analgesic agents. |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US6765007B1 (en) |
| EP (1) | EP0874632B1 (en) |
| JP (2) | JP4711360B2 (en) |
| KR (1) | KR100338829B1 (en) |
| CN (1) | CN1132582C (en) |
| AP (2) | AP747A (en) |
| AR (1) | AR005456A1 (en) |
| AT (1) | ATE220910T1 (en) |
| AU (1) | AU713090B2 (en) |
| BG (1) | BG63488B1 (en) |
| BR (1) | BR9706982A (en) |
| CY (1) | CY2390B1 (en) |
| CZ (1) | CZ287205B6 (en) |
| DE (1) | DE69714215T2 (en) |
| DK (1) | DK0874632T3 (en) |
| DZ (1) | DZ2159A1 (en) |
| EA (1) | EA001946B1 (en) |
| EG (1) | EG23684A (en) |
| ES (1) | ES2180922T3 (en) |
| GB (1) | GB9600847D0 (en) |
| HU (1) | HU225472B1 (en) |
| IL (1) | IL124913A0 (en) |
| MX (1) | MX9805713A (en) |
| MY (1) | MY127527A (en) |
| NO (1) | NO315689B1 (en) |
| NZ (1) | NZ326769A (en) |
| OA (1) | OA10812A (en) |
| PE (1) | PE35498A1 (en) |
| PL (1) | PL187291B1 (en) |
| PT (1) | PT874632E (en) |
| SK (1) | SK282132B6 (en) |
| TR (1) | TR199800954T2 (en) |
| TW (1) | TW434016B (en) |
| UA (1) | UA63897C2 (en) |
| UY (2) | UY24437A1 (en) |
| WO (1) | WO1997025990A1 (en) |
| ZA (1) | ZA97310B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007037790A2 (en) * | 2005-06-08 | 2007-04-05 | Elan Corporation, Plc | Modified release famciclovir compositions |
| AU2010265866B2 (en) | 2009-06-26 | 2012-07-12 | Taris Biomedical Llc | Solid drug tablets for implantable drug delivery devices |
| JP2015063521A (en) * | 2013-09-02 | 2015-04-09 | 科研製薬株式会社 | Tablet having high drug content and method for producing the same |
| CN104434852B (en) * | 2013-09-18 | 2018-11-20 | 北京韩美药品有限公司 | Famciclovir vertical compression piece and preparation method thereof |
| CN112587491B (en) * | 2021-01-03 | 2022-08-23 | 迪沙药业集团有限公司 | Famciclovir tablet composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2671970A1 (en) * | 1991-01-30 | 1992-07-31 | Wellcome Found | DISPERSABLE TABLETS IN WATER. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3421800C1 (en) * | 1984-06-12 | 1986-04-17 | Maschinen und Werkzeugbau Michael Brümmer GmbH, 8804 Dinkelsbühl | Elastic roller for treating a thermoplastic film |
| EP0182024B1 (en) * | 1984-09-20 | 1991-04-03 | Beecham Group Plc | Purine derivatives and their pharmaceutical use |
| CA2103050A1 (en) | 1991-05-15 | 1992-11-16 | Yung-Chi Cheng | Determination of prodrugs metabolizable by the liver and therapeutic use thereof |
| GB9303157D0 (en) * | 1993-02-17 | 1993-03-31 | Scotia Holdings Plc | Treatment of a group of related disorders |
| IL111138A (en) | 1993-10-05 | 1997-04-15 | Smithkline Beecham Plc | Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia |
| JP3702594B2 (en) * | 1997-08-07 | 2005-10-05 | 株式会社明電舎 | Parameter adjustment method and apparatus |
-
1996
- 1996-01-16 GB GBGB9600847.9A patent/GB9600847D0/en active Pending
-
1997
- 1997-01-02 AP APAP/P/1997/000911A patent/AP747A/en active
- 1997-01-10 UY UY24437A patent/UY24437A1/en not_active IP Right Cessation
- 1997-01-13 CZ CZ19982254A patent/CZ287205B6/en not_active IP Right Cessation
- 1997-01-13 PL PL97327922A patent/PL187291B1/en unknown
- 1997-01-13 AP APAP/P/1998/001298A patent/AP1114A/en active
- 1997-01-13 CN CN97191703A patent/CN1132582C/en not_active Expired - Lifetime
- 1997-01-13 SK SK956-98A patent/SK282132B6/en not_active IP Right Cessation
- 1997-01-13 UA UA98063199A patent/UA63897C2/en unknown
- 1997-01-13 EP EP97901539A patent/EP0874632B1/en not_active Expired - Lifetime
- 1997-01-13 IL IL12491397A patent/IL124913A0/en not_active IP Right Cessation
- 1997-01-13 KR KR1019980705371A patent/KR100338829B1/en not_active Expired - Lifetime
- 1997-01-13 JP JP52569297A patent/JP4711360B2/en not_active Expired - Lifetime
- 1997-01-13 US US09/101,926 patent/US6765007B1/en not_active Expired - Lifetime
- 1997-01-13 BR BR9706982A patent/BR9706982A/en not_active IP Right Cessation
- 1997-01-13 NZ NZ326769A patent/NZ326769A/en not_active IP Right Cessation
- 1997-01-13 WO PCT/EP1997/000195 patent/WO1997025990A1/en not_active Ceased
- 1997-01-13 AU AU15418/97A patent/AU713090B2/en not_active Expired
- 1997-01-13 EA EA199800573A patent/EA001946B1/en not_active IP Right Cessation
- 1997-01-13 TR TR1998/00954T patent/TR199800954T2/en unknown
- 1997-01-13 AT AT97901539T patent/ATE220910T1/en active
- 1997-01-13 HU HU9901021A patent/HU225472B1/en unknown
- 1997-01-13 DE DE69714215T patent/DE69714215T2/en not_active Expired - Lifetime
- 1997-01-13 ES ES97901539T patent/ES2180922T3/en not_active Expired - Lifetime
- 1997-01-13 DK DK97901539T patent/DK0874632T3/en active
- 1997-01-13 PT PT97901539T patent/PT874632E/en unknown
- 1997-01-14 TW TW086100335A patent/TW434016B/en not_active IP Right Cessation
- 1997-01-14 AR ARP970100130A patent/AR005456A1/en active IP Right Grant
- 1997-01-14 EG EG4697A patent/EG23684A/en active
- 1997-01-15 PE PE1997000022A patent/PE35498A1/en not_active IP Right Cessation
- 1997-01-15 DZ DZ970004A patent/DZ2159A1/en active
- 1997-01-15 MY MYPI97000137A patent/MY127527A/en unknown
- 1997-01-15 ZA ZA9700310A patent/ZA97310B/en unknown
- 1997-05-16 UY UY24556A patent/UY24556A1/en not_active IP Right Cessation
-
1998
- 1998-07-15 NO NO19983259A patent/NO315689B1/en not_active IP Right Cessation
- 1998-07-15 MX MX9805713A patent/MX9805713A/en unknown
- 1998-07-15 BG BG102638A patent/BG63488B1/en unknown
- 1998-07-16 OA OA9800116A patent/OA10812A/en unknown
-
2003
- 2003-11-28 CY CY0300085A patent/CY2390B1/en unknown
-
2008
- 2008-11-19 JP JP2008295818A patent/JP2009091362A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2671970A1 (en) * | 1991-01-30 | 1992-07-31 | Wellcome Found | DISPERSABLE TABLETS IN WATER. |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103068373A (en) | Contains 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactate mono Hydrate pharmaceutical composition | |
| EP1043984A1 (en) | Pharmaceutical compositions containing bupropion hydrochloride and an inorganic acid stabilizer | |
| AP747A (en) | Pharmaceutical compositions in the form of a tablet containing famciclovir. | |
| US20070172521A1 (en) | Levetiracetam formulations and methods for their manufacture | |
| JP2009091362A6 (en) | High content famciclovir tablets | |
| US20060147519A1 (en) | Process for the preparation of robust formulations of valacyclovir hydrochloride tablets | |
| CA2240462C (en) | High-content famciclovir tablets | |
| HK1016473B (en) | High-content famciclovir tablets | |
| EP1501521B1 (en) | Long acting compositions comprising zidovudine and/or lamivudine | |
| US20020183308A1 (en) | Benazepril Hydrochloride tablet formulations | |
| CN115212206B (en) | Medicinal composition containing pirfenidone and preparation method thereof | |
| CN115518046B (en) | Voriconazole dispersible tablet and preparation method thereof | |
| JP2009538905A (en) | Stable formulation comprising moisture sensitive drug and method for producing the same | |
| JPH06227995A (en) | Stabilized solid preparation | |
| EP3372227A1 (en) | Tablet formulation of adefovir dipivoxil | |
| CN116687875A (en) | Ukenafil hydrochloride pharmaceutical composition and preparation method and application thereof | |
| JP2020193229A (en) | Oral solid composition, production method thereof, and oral tablet obtained by the production method | |
| HK1077741B (en) | Oral fludara of high-purity formulation with quick release of active ingredient | |
| HK1077741A1 (en) | Oral fludara of high-purity formulation with quick release of active ingredient |